(24/7 MARKET NEWS) – XORTX Therapeutics Inc. (NASDAQ: XRTX) announced, this morning, positive topline results from the XRX-OXY-101 – Bridging Pharmacokinetics Clinical Trial characterizing the pharmacokinetics of the Company’s proprietary formulation of oral oxypurinol, XORLO, which showed that XORLO was well tolerated across the various dosing regimens.
XORTX Therapeutics is trading at $1.03, up $0.2472 (+31.58%), on volume of 18 million shares.
Its 52-week range is $0.663 to $2.48. Its next key inflection points are $1.49 and $1.58, and this morning’s premarket high of $1.82.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
